Table 2.
Estimates of the impact of COVID-19 epidemic on disease burden during the first and second six months of the COVID-19 time period
| Outcomes | April 2020-September 2020 | October 2020-March 2021 | ||||
|---|---|---|---|---|---|---|
| Observeda | Expecteda | Ratio [95% CI]b | Observeda | Expecteda | Ratio [95% CI]b | |
| Total number of outpatient visits | 196,300 | 216,822 | 0.91 [0.82, 1.00] | 187,573 | 186,136 | 1.01 [0.81,1.23] |
| No of visits with a malaria diagnosis | 75,825 | 82,8842 | 0.92 [0.76, 1.14] | 60,032 | 50,050 | 1.20 [0.75, 1.84] |
| Number of non-malaria visits | 120,475 | 123,902 | 0.97 [0.92, 1.04] | 127,541 | 118,890 | 1.07 [0.95, 1.21] |
| % Suspected/visits | 61.9% | 64.1% | 0.97 [0.93, 1.04] | 61.6% | 61.9% | 0.99 [0.89,1.22] |
| % Tested with RDT | 85.4% | 88.3% | 0.97 [0.91, 1.01] | 80.3% | 92.2% | 0.87 [0.78,0.97] |
| % Malaria cases prescribed AL | 94.2% | 95.2% | 0.99 [0.98, 1.00] | 89.1% | 94.4% | 0.94 [0.90, 0.99] |
aEstimates reported as the total number of visits or mean proportion during the 1-year post-policy period
bFor visit outcomes, this represents an incidence rate ratio; for proportions, a relative percent ratio. Assumed a constant population at-risk over the study period